ESC-HFA 2023: Late-Breaking Science Video Collection
Published: 23 May 2023
-
Views:
2938
-
Likes:
7
-
Views:
2938
-
Likes:
7
-
Up Next -
6m 54s -
3m 11sPart 2 | Session 3 APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis -
4m 45sPart 2 | Session 4 DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction -
8m 47sPart 2 | Session 5 DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF -
4m 53sPart 2 | Session 6 NUDGE-FLU: Increasing Influenza Vaccination in HF Patients -
3m 56sPart 2 | Session 7 DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF -
5m 11sPart 2 | Session 8 TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure -
8m 22sPart 2 | Session 9 Diagnosis in Heart Failure in Women -
3m 50sPart 2 | Session 10 Dapagliflozin and Peripheral Arterial Disease in Heart Failure
-
26m 30sPart 1 | Session 1 Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney Harriette Van Spall, Tariq Ahmad, Jozine ter Maaten
-
5m 48sPart 1 | Session 2 The PARAGLIDE-HF Trial Harriette Van Spall, Robert Mentz
-
13m 32sPart 1 | Session 3 HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi Harriette Van Spall, James L Januzzi
-
4m 3sPart 1 | Session 4 TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction James L Januzzi, Harriette Van Spall
Overview
Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.
Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.
For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
About the episode
Dr Jasper Brugts (Thoraxcenter, NL) joins us to outline the findings and summarise the take-home messages from the MONITOR-HF trial.
MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of ejection fraction. Patients were randomly assigned (1:1) to haemodynamic monitoring (CardioMEMS-HF system, Abbott Laboratories) or standard care. Findings presented at Heart Failure 2023 showed PA-guided therapy in addition to SoC with contemporary GDMT resulted in a significant improvement in quality of life and substantial reduction in total HFHs.
Interview Questions:
1. What is the importance of MONITOR-HF?
2. Can you tell us about the CardioMEMS system?
3. What is the study design, patient population and outcomes measures?
4. What are the finding presented at HFA 23?
5. How did MONITOR-HF compare to trials such as CHAMPION and GUIDE-HF?
6. What are the implications for the use of diuretics in GDMT therapy?
7. What are the next steps?
Faculty Biographies
Jasper J Brugts
Heart Failure Cardiologist
Dr Jasper J Brugts is a Heart Failure Cardiologist at Erasmus University Medical Centre, Rotterdam, NL.
He is also a clinical epidemiologist and clinical trialist.
Comments